US Broker Ratings

Kamada Ltd. (KMDA) Stock Analysis: Exploring a 62% Potential Upside in Healthcare

Kamada Ltd. (NASDAQ: KMDA), a specialty and generic drug manufacturer headquartered in Israel, is attracting significant attention from investors. With a focus on plasma-derived protein therapeutics, Kamada’s diverse product portfolio..

Prothena Corporation plc (PRTA) Stock Analysis: 143.51% Potential Upside with Cutting-Edge Biotechnology Innovations

Prothena Corporation plc (NASDAQ: PRTA), a Dublin-based biotechnology company, is making waves in the healthcare sector with its promising pipeline of novel therapies aimed at tackling diseases caused by protein..

Weave Communications, Inc. (WEAV) Stock Analysis: 71% Potential Upside with Strong Buy Ratings

For investors seeking opportunities in the healthcare technology sector, Weave Communications, Inc. (WEAV) presents a compelling case. Specializing in health information services, Weave Communications offers a diverse suite of products..

AngioDynamics, Inc. (ANGO) Stock Analysis: Exploring a 92% Potential Upside for Investors

AngioDynamics, Inc. (NASDAQ: ANGO), a prominent player in the healthcare sector, is renowned for its innovative contributions to medical technology. Specializing in medical instruments and supplies, the company is carving..

Cel-Sci Corporation (CVM) Investor Outlook: Analyzing the 767% Potential Upside in Biotech Innovation

In the fast-evolving world of biotechnology, Cel-Sci Corporation (CVM) stands as an intriguing prospect for investors. With a focus on harnessing the power of the immune system to combat cancer..

Celcuity Inc. (CELC) Stock Analysis: Exploring a 5.96% Potential Upside in the Biotechnology Sector

Celcuity Inc. (NASDAQ: CELC), a prominent player in the biotechnology sector, is drawing investor attention with its promising drug development initiatives and a notable potential upside of 5.96%, as indicated..

Myriad Genetics, Inc. (MYGN) Stock Analysis: Exploring a 59% Potential Upside in the Diagnostics Space

For investors seeking opportunities in the healthcare sector, Myriad Genetics, Inc. (NASDAQ: MYGN) presents a compelling case. This US-based molecular diagnostics company, with a market cap of approximately $475.39 million,..

Butterfly Network, Inc. (BFLY): Investor Outlook on a 56.73% Potential Upside

Butterfly Network, Inc. (BFLY), a pioneer in the healthcare sector, is making waves with its innovative medical devices, particularly in the ultrasound imaging domain. Known for its cutting-edge Butterfly iQ+..

CeriBell, Inc. (CBLL) Stock Analysis: 45.52% Potential Upside with Strong Buy Ratings in Medical Devices Sector

CeriBell, Inc. (CBLL), a U.S.-based medical technology company, is making waves in the healthcare sector with its innovative solutions for the diagnosis and management of serious neurological conditions. Focused primarily..

AtaiBeckley Inc. (ATAI): Biotech Stock with a Staggering 265% Potential Upside and Strong Buy Ratings

AtaiBeckley Inc. (ATAI), a dynamic player in the biotechnology sector, is capturing investor attention with its substantial growth potential and an impressive 265.24% potential upside, according to analyst ratings. As..

STAAR Surgical Company (STAA) Stock Analysis: Exploring the 38.40% Potential Upside

STAAR Surgical Company (NASDAQ: STAA), a key player in the medical instruments and supplies industry, has been generating buzz among healthcare investors for its innovative ocular products. Known for its..

Tectonic Therapeutic, Inc. (TECX) Stock Analysis: Exploring a 247% Potential Upside in Biotech Innovation

Tectonic Therapeutic, Inc. (NASDAQ: TECX) stands out in the biotechnology sector with its innovative approach to developing GPCR-targeted biologic medicines. Despite a current price of $22.86 and a recent slight..

SIGA Technologies Inc. (SIGA) Stock Analysis: Exploring the Healthcare Innovator’s 39.94% ROE and Strategic Positioning

SIGA Technologies Inc. (NASDAQ: SIGA), a prominent player in the healthcare sector, stands out as a commercial-stage pharmaceutical company with a focus on the health security market. Headquartered in New..

Bioventus Inc. (BVS) Stock Analysis: An 82.70% Potential Upside Attracts Bullish Investor Sentiment

Bioventus Inc. (BVS), a key player in the healthcare sector focusing on medical devices, is capturing attention with an exceptional potential upside of 82.70%. This Durham, North Carolina-based company, founded..

Personalis, Inc. (PSNL) Stock Analysis: A 50% Upside Potential Amidst Strategic Innovations

For investors with a keen eye on the healthcare sector, Personalis, Inc. (NASDAQ: PSNL) presents an intriguing opportunity. Specializing in advanced cancer genomic tests and services, the company is at..

REGENXBIO Inc. (RGNX) Investor Outlook: Exploring a 202% Potential Upside with Promising Gene Therapy Innovations

REGENXBIO Inc. (NASDAQ: RGNX) is a prominent player in the biotechnology sector, with a focus on developing innovative gene therapy solutions through its proprietary NAV Technology Platform. With a market..

Septerna, Inc. (SEPN) Stock Analysis: Biotechnology Innovator with a 38.53% Potential Upside

In the dynamic world of biotechnology, Septerna, Inc. (NASDAQ: SEPN) emerges as a compelling player with a focus on developing innovative treatments for a spectrum of diseases. Based in South..

Pharvaris N.V. (PHVS) Stock Analysis: A Promising 85% Potential Upside for Biotech Investors

Pharvaris N.V. (NASDAQ: PHVS), a Switzerland-based biotechnology firm, is making waves in the healthcare sector with its innovative approach to treating rare diseases, particularly angioedema. With a market capitalization of..

EyePoint, Inc. (EYPT) Stock Analysis: A Potential 183% Upside in Biotech Breakthrough

Investors with an eye on the biotechnology sector might find EyePoint, Inc. (NASDAQ: EYPT) a compelling opportunity, especially given its potential upside of 183.45%. EyePoint is carving a niche in..

Cross Country Healthcare, Inc. (CCRN) Stock Analysis: Navigating Through Challenges with a 13.62% Upside Potential

Cross Country Healthcare, Inc. (NASDAQ: CCRN), a significant player in the healthcare sector specializing in medical care facilities, is currently trading at $8.74, which reflects a slight decline of 0.02%...

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds